B-type Natriuretic Peptide Testing in Heart Failure Diagnosis and Management

Diagnostic Applications

The American Heart Association recommends BNP or NT-proBNP testing in the acute setting to rule out or confirm the diagnosis of heart failure in patients with suspected heart failure presenting with acute dyspnea, with BNP testing having high sensitivity (90%) and moderate specificity (76%) for diagnosing heart failure in patients presenting with acute dyspnea in emergency departments 1, 2
Using a BNP cut-off of 100 pg/mL provides 81% diagnostic accuracy in determining heart failure as the etiology of acute dyspnea, according to the American College of Cardiology 1, 3
For NT-proBNP, cut-points of 450 pg/mL (age <50 years) and 900 pg/mL (age ≥50 years) are highly sensitive and specific for diagnosing acute heart failure, as recommended by the American Heart Association 1, 3
BNP testing in emergency departments improves evaluation and treatment of patients with acute dyspnea, reducing time to discharge and total treatment costs, with a Class IIa recommendation from the American College of Cardiology 1, 2

BNP and NT-proBNP testing can help exclude heart failure among patients with signs and symptoms suspicious of heart failure in non-acute settings, with a Class IIa recommendation from the American Heart Association 1, 4
In primary care settings, NT-proBNP testing improves diagnostic accuracy of heart failure by general practitioners, according to the American Academy of Family Physicians 1, 3
For patients without previous myocardial infarction who have suspected heart failure, serum natriuretic peptide measurement should be performed before echocardiography, as recommended by the American College of Physicians 5

BNP or NT-proBNP testing can provide useful addition to clinical assessment for risk stratification in selected situations, with a Class IIa recommendation from the American Heart Association 6
Serial BNP or NT-proBNP measurements may be used to track changes in risk profiles and clinical status among heart failure patients when additional risk stratification is required, according to the American College of Cardiology 6

Several clinical factors influence BNP levels, including age, sex, renal function, body habitus, thyroid function, and anemia, as noted by the American Heart Association 3
Obesity is associated with lower BNP and NT-proBNP levels across the spectrum of heart failure and should be interpreted with caution, according to the American College of Cardiology 3
Diastolic dysfunction, mitral regurgitation, right ventricular dysfunction, recent heart surgery, and other cardiac structural or functional abnormalities can significantly influence BNP levels, as recommended by the American Heart Association 1, 3

When BNP or NT-proBNP levels are elevated, patients should undergo echocardiography and specialist evaluation within 2 weeks if levels are high, or within 6 weeks if levels are moderately raised, as recommended by the American College of Physicians 5
BNP and NT-proBNP have comparable diagnostic and prognostic abilities, though there are differences in half-lives, variability, production, and renal clearance, according to the American Heart Association 1, 3

A normal BNP (<100 pg/mL) or NT-proBNP (<400 pg/mL) makes heart failure unlikely in untreated patients with a negative predictive value of approximately 90-94%, but false negatives can occur, and the diagnosis must rely on echocardiography combined with clinical assessment, ECG findings, and evaluation of specific conditions that suppress natriuretic peptide levels, as recommended by the European Society of Cardiology 7, 8

The European Society of Cardiology suggests that if the ECG is completely normal, heart failure—especially with systolic dysfunction—is unlikely (<10% probability), and an abnormal ECG warrants further investigation regardless of normal BNP 7, 8, 9
Echocardiography is the diagnostic standard and must be performed to confirm or exclude heart failure when clinical suspicion persists despite normal BNP, according to the European Heart Journal 7, 8, 10
The American College of Cardiology recommends assessing left ventricular ejection fraction (LVEF), wall motion abnormalities, valvular disease, and diastolic dysfunction during echocardiography 10
For HFpEF diagnosis, three conditions must be satisfied: (1) symptoms/signs of heart failure, (2) normal or mildly abnormal LVEF (45-50%), and (3) evidence of abnormal left ventricular stiffness, as stated by the European Society of Cardiology 7, 8, 9

HFpEF/diastolic dysfunction is a common false-negative scenario, where BNP may be less elevated in these patients, and echocardiographic assessment of diastolic function is essential, as recommended by the European Society of Cardiology 7, 8, 9
Flash pulmonary edema without time for BNP elevation is another false-negative scenario, particularly in acute mitral regurgitation or hypertensive crisis, as described by the European Heart Journal 7, 8
Patients already on heart failure treatment may have suppressed BNP levels, and clinical suspicion for heart failure should remain high despite normal BNP, according to the European Society of Cardiology 7